StimCardio Medical (formerly CardiaCare)

What StimCardio Medical (formerly CardiaCare) does

StimCardio Medical (formerly CardiaCare) is a clinical-stage private medical device company developing a non-invasive wearable neuromodulation platform for the management of atrial fibrillation. Founded in 2015 in Israel by Amos Ziv and rebranded to StimCardio in 2025, the company is headquartered in Los Angeles with engineering and R&D operations in Austin, Texas, and scientific operations in Ness Ziona, Israel. The target patient population comprises individuals with paroxysmal atrial fibrillation and post-ablation patients experiencing recurrence, segments underserved by antiarrhythmic drugs, invasive ablation procedures, and cardioversion.

The company's lead asset is Rhyvive, a wrist-worn wearable integrating ECG and optical sensors with embedded stimulation electrodes, paired with a companion mobile application. Rhyvive delivers personalized median-vagus nerve stimulation (mVNS) at the wrist, modulating autonomic nervous system activity and cardiac rhythm. Physiological data is transmitted to the StimCardio Health Cloud, a machine learning-enabled platform that performs longitudinal pattern analysis, arrhythmia precursor detection, and adaptive closed-loop personalization, complemented by a provider-facing clinical dashboard for electrophysiologists. The company has completed a feasibility study (n=10), a randomized sham-controlled pilot (n=31), and a mechanism-of-action study (n=25), with pivotal trial preparation underway and FDA clearance targeted for 2027.

StimCardio is pre-revenue with no commercially approved products. Approximately $25M in disclosed funding has been raised across a September 2023 seed extension (Solardis Health Ventures) and a 2025 Series A led by Metis MedTech. The planned commercial model is a physician-prescribed at-home deployment of Rhyvive, potentially combined with subscription-based cloud analytics and remote patient monitoring. Distribution is currently confined to clinical trial participants; commercial launch is contingent on FDA clearance and will be anchored through KOL relationships, scientific conferences, and accelerator partnerships including MedTech Innovator and HeartX.

Name

StimCardio Medical (formerly CardiaCare)

Legal name

StimCardio Medical Inc.

Website

https://www.stimcardio.com/

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

StimCardio Medical is a clinical-stage medical device company developing Rhyvive, a non-invasive wrist-worn wearable that delivers median-vagus nerve stimulation with continuous cardiac monitoring and cloud-based machine learning to treat paroxysmal atrial fibrillation and post-ablation recurrence.

Ownership category

akta.pro rank

Product category

Cardiac Neuromodulation Medical Devices

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

akta.pro secondary industries

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG)

Keywords

• Wearable neuromodulation devices
• Atrial fibrillation therapy
• Cardiac rhythm management
• Non-invasive medical devices
• Digital health platforms

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Rhyvive Wearable Device Sales: StimCardio's Rhyvive wearable is currently in clinical investigation and not yet approved for commercial sale. Planned as physician-prescribed medical device for at-home use targeting atrial fibrillation patients. Revenue model expected to involve device sales potentially combined with subscription components for cloud analytics and ongoing monitoring services.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

StimCardio Medical is developing a non-invasive, wearable neuromodulation platform centered on the Rhyvive wrist-worn device, which delivers personalized median-vagus nerve stimulation (mVNS) while continuously monitoring cardiac and autonomic signals via integrated ECG and optical sensors. Data is transmitted to the StimCardio Health Cloud, a cloud-based platform using machine learning for pattern analysis, personalization, and adaptive closed-loop therapy. The platform includes a patient-facing mobile application and a provider-facing clinical dashboard, targeting atrial fibrillation management with FDA clearance targeted for 2027.

Product overview

StimCardio Medical offers a unified therapeutic platform centered on the Rhyvive wrist-worn wearable, which delivers personalized median-vagus neuromodulation (mVNS) while continuously monitoring cardiac and autonomic signals via integrated ECG and optical sensors. Physiological data flows to the StimCardio Health Cloud, a cloud-based platform that uses machine learning to enable pattern analysis, personalization, and adaptive closed-loop behavior. The ecosystem includes a patient-facing mobile application for therapy management and symptom tracking, and a provider-facing clinical dashboard enabling remote patient monitoring. This closed-loop architecture enables the system to adapt neuromodulation parameters based on individual physiological patterns over time.

Differentiator

Problem solved

Functional benefit

Brands

• Rhyvive: The wrist-worn wearable component of the StimCardio platform, integrating ECG and optical sensors, embedded stimulation electrodes, secure data transmission, and a companion mobile application. It delivers non-invasive median-vagus neuromodulation (mVNS) for atrial fibrillation management.

Products and services

• Rhyvive Wearable Device

Quantifiable outcome

• Reduced AF recurrence rates by close to 50% after 8 weeks of therapy
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• Ziv Healthcare LtdcoreStrategic or Co-development PartnerZiv Healthcare Ltd is an affiliate of StimCardio Medical Inc. The companies jointly develop the wearable neuromodulation technology and device. Ziv Healthcare is responsible for device development including related software, algorithms, know-how, documentation, product and development materials, and related improvements. They act as joint controllers for personal data processing in clinical trials.
• Mount Sinai Health SystemcoreStrategic or Co-development PartnerProf. Vivek Y. Reddy, Director of Cardiac Arrhythmia Services at The Mount Sinai Hospital, serves as Senior Medical Advisor and lead investigator on clinical studies. Mount Sinai serves as lead investigator on multiple multinational clinical trials evaluating the technology.
• HealthTech Arkansas / HeartX AcceleratorflagshipStrategic or Co-development PartnerSelected for HeartX Cardiovascular Accelerator 2025-2026 cohort. Partnership facilitates hospital pilot projects and clinical trials with leading cardiovascular programs across the United States.
• MedAxiomflagshipStrategic or Co-development PartnerPartnership with MedAxiom, the leading authority in cardiovascular organizational performance, powers the HeartX accelerator program and provides access to cardiovascular provider networks for clinical validation.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Electrocore: Developer of non-invasive vagus nerve stimulation (nVNS) devices including gammaCore for headache and exploratory cardiac/AF applications. Closely comparable to StimCardio as a non-invasive peripheral neuromodulation platform targeting autonomic pathways, though Electrocore is more clinically established in migraine and earlier in cardiac indications.
• CVRx: Developer of Barostim, an implantable neuromodulation device FDA-approved for heart failure. Direct peer in cardiovascular neuromodulation with cleared regulatory pathway and commercial-stage revenues; differs from StimCardio in invasiveness (implant vs. wearable) and primary indication (HF vs. AF).

Emerging players

• iRhythm Technologies: Commercial-stage digital cardiac monitoring company (Zio long-term continuous ECG patch) with AI-powered arrhythmia detection. Comparable to StimCardio's wearable sensing + cloud analytics architecture and serves the same electrophysiology prescribing channel, though iRhythm is diagnostic-only with no therapeutic neuromodulation.
• AliveCor: Maker of KardiaMobile, a consumer/clinical-grade single-lead ECG device with AI-based AF detection and remote monitoring. Comparable ECG-and-cloud analytics overlap with StimCardio's Rhyvive, though AliveCor is diagnostic and consumer-direct rather than a prescribed therapeutic.
• Eko Health: AI-powered digital stethoscope and cardiac monitoring platform with FDA-cleared ECG and AF detection algorithms. Comparable in combining wearable ECG sensors with cloud-based ML arrhythmia analysis, though Eko focuses on point-of-care auscultation rather than chronic wearable therapy.
• Inspire Medical Systems: Commercial-stage implantable neuromodulation company (hypoglossal nerve stimulation for obstructive sleep apnea) that established a precedent for neuromodulation category creation and payer coverage. Useful analog for StimCardio's path from novel neuromodulation to commercial reimbursement, though modality and indication differ.

Broad incumbents

• Boston Scientific: Acquired Farapulse (pulsed-field ablation) for $800M+ in 2021 and operates a broad cardiac rhythm management franchise. The dominant incumbent competing for AF treatment dollars; StimCardio's neuromodulation approach is positioned as adjuvant to or alternative for Boston Scientific's ablation portfolio.
• AtriCure: Commercial-stage surgical and catheter ablation company focused on atrial fibrillation, including the Isolator Synergy and cryoSPHERE devices. Direct incumbent in the AF ablation space StimCardio targets as an adjuvant/non-invasive alternative.
• Medtronic: Largest cardiac rhythm management incumbent with pacemakers, ICDs, CRTs, and the Arctic Front cryoablation franchise. Sets the standard-of-care benchmark that any wearable neuromodulation for AF must outperform on cost, convenience, or patient selection.

Regional players

• Axonics: Developer of miniaturized, long-lived sacral neuromodulation implants for incontinence. Comparable as a pure-play neuromodulation company with successful commercialization, FDA-cleared platform, and strong reimbursement coverage — adjacent therapeutic area but analogous commercial pathway.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/StimCardio

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StimCardio Medical (formerly CardiaCare)